Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 32150268.
- Also identified by DOI 10.1001/jamanetworkopen.2020.0423 and PMC identifier 7063495.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This cross-sectional study estimates the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs.
Medical subject headings
- Antineoplastic Agents, Immunological
- Eligibility Determination
- Neoplasms
- Patient Selection
- Practice Patterns, Physicians'